Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies
Revised Law Includes Designated Funding for Rare Diseases
Nonprofit issues challenge to accelerate treatments for every person with CF
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.